ARID1A gene mutation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:27:57 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png ARID1A gene mutation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Simvastatin with Nivolumab and Oxaliplatin for Patients with Advanced Stomach or Esophageal Cancer with ARID1A Mutation https://clinicaltrials.eu/trial/study-of-simvastatin-with-nivolumab-and-oxaliplatin-for-patients-with-advanced-stomach-or-esophageal-cancer-with-arid1a-mutation/ Wed, 29 Apr 2026 15:05:09 +0000 https://clinicaltrials.eu/trial/study-of-simvastatin-with-nivolumab-and-oxaliplatin-for-patients-with-advanced-stomach-or-esophageal-cancer-with-arid1a-mutation/ This clinical trial is focused on studying a type of cancer called advanced gastroesophageal carcinoma, which affects the stomach and esophagus. The study specifically looks at cases where the cancer is HER2 negative and has a genetic change known as ARID1A mutation. The trial aims to evaluate the effectiveness of a treatment combination that includes the drug Simvastatin, which is commonly used to lower cholesterol, alongside Nivolumab and Oxaliplatin-based chemotherapy. Nivolumab, also known by its code name BMS936558, is a medication that helps the immune system fight cancer, while Oxaliplatin is a chemotherapy drug that kills cancer cells.

The purpose of the study is to see how well this combination works in preventing the cancer from getting worse over a year. Participants will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will also include other medications like Fluorouracil, known as 5-FU, and Calcium Levofolinate, which help enhance the effects of chemotherapy. Additionally, some participants may receive Simvastatin in tablet form to see if it improves treatment outcomes.

Throughout the study, participants will be monitored to assess how the cancer responds to the treatment and to check for any side effects. The study will last up to 60 weeks, during which the health and quality of life of the participants will be regularly evaluated. The goal is to determine if this treatment approach can help patients live longer without the cancer progressing. The trial will also compare results with a group of patients who do not have the ARID1A mutation to see if there are differences in treatment effectiveness.

]]>